ExoLuminate Study for Early Detection of Pancreatic Cancer
Recruiting now
Conditions studied: Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
In brief
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
Key facts
- Study ID
- NCT05625529
- Run by
- Biological Dynamics
- People needed
- 1000
- Starts
- 2022-12-19
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2025-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ≥18 years old.
- Meeting criteria for one of the study cohorts.
- Capable of giving informed consent.
- Able to provide a blood sample.
You may not qualify if…
- < 18 years old.
- Pregnancy.
- Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
- Prior organ transplant or bone marrow transplant.
- History of fainting or other adverse effects when blood is drawn.
- Any condition that, in the opinion of the investigator, should preclude enrollment.
Where it is running
- Biological Dynamics — San Diego, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.